Copyright © Inderes 2011 - present. All rights reserved.

Revenio Group

18.24 EUR

-0.33 %

14,239 following
Corporate customer

REG1V

NASDAQ Helsinki

Medical Equipment & Services

Health Care

-0.33 %
-17.09 %
-18.57 %
-20.70 %
-24.63 %
-34.90 %
-50.84 %
-67.77 %
+860.00 %

Revenio is a global provider of comprehensive eye care diagnostic solutions. The group offers fast, user-friendly, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and macular degeneration (AMD). Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as software solutions under the iCare brand. In 2023, the Group’s net sales totaled EUR 96.6 million, with an operating profit of EUR 26.3 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

Read more
Market cap
486.66M EUR
Turnover
621.66K EUR
P/E (adj.) (26e)
20.57
EV/EBIT (adj.) (26e)
15.2
P/B (26e)
3.82
EV/S (26e)
3.77
Dividend yield-% (26e)
2.74 %
Coverage
Recommendation
Buy
Target price
24.00 EUR
Updated
2026-02-12
Disclaimer
Juha Kinnunen
Juha Kinnunen

Analyst

Latest research

Latest analysis report

Released: 2026-02-12

Latest extensive report

Released: 2025-01-21

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
15/4
2026

General meeting '26

28/4
2026

Interim report Q1'26

6/8
2026

Interim report Q2'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Revenio Q4'25 preview: Valuation reaches historic lows
Research by
Juha Kinnunen

Revenio Q4'25 preview: Valuation reaches historic lows

Revenio's valuation has fallen to a historically low level, as the industry faces concerns, especially after Zeiss's grim profit warning. We consider the concerns regarding Revenio to be exaggerated and estimate the company's earnings to be firmly on an upward trend this year.

Revenio Group
Revenio Q3'25: Q4 will decide this year too
Research by
Juha Kinnunen

Revenio Q3'25: Q4 will decide this year too

Revenio's Q3 earnings fell short of our overly optimistic expectations, but on the other hand, the Q4 outlook appears better than we anticipated. There have been no dramatic revisions in the outlook for the coming years, but the market is showing at least small signs of recovery.

Revenio Group
Forum discussions
Revenio has really started to look interesting after the massive correction in its stock price and valuation multiples. I know as much about intraocular pressure monitors as a pig knows about football, but the technology is apparently still world-class. The outlook is said to be ...
2/13/2026, 10:35 AM
by Ituhippinen
51
I’ve been thinking the same, but if I recall correctly, insiders aren’t allowed to trade when acquisition negotiations are ongoing. Revenio has publicly commented on exploring M&A opportunities, and apparently, expenses from these investigations have been recorded in recent years...
2/13/2026, 10:53 AM
by Tyhjätasku
31
I think of it this way: recurring revenue can grow by any amount, but its relative development compared to total revenue is dependent on how much device sales grow. So, if recurring revenue grows strongly in relative terms, it might even be concerning, as it would indicate that device...
2/15/2026, 5:04 PM
by Tyhjätasku
26
Greetings to the thread. I’ve jumped back on board again. I have cashed out twice from this over the last 9 years. Time will tell how it goes this time. Reasons for getting back in now: low valuation combined with interesting prospects despite the antics of US politicians the ongoing...
2/13/2026, 1:34 PM
by M
23
An interesting report, not quite according to expectations, but not bad. First of all, I must say thanks to Juha for the update before the interim report. It provided me with new information about Zeiss’s situation. There was a lot of talk about the lack of growth, but it was reasonable...
2/12/2026, 8:15 PM
by Tyhjätasku
20
I recalled that Revenio mentioned in its 2024 annual report that “recurring” revenue—i.e., revenue from the sale of software, sensors, and service contracts—was “nearly a third,” and indeed it was. Now it was mentioned that this same share again accounted for “nearly a third.” It...
2/15/2026, 3:07 PM
by Anonyymi123
16
I also think that purchases simply cannot be made right now while potential M&A negotiations are ongoing. The dividend proposal and communication have been such that an acquisition could be seen very soon. Furthermore, if negotiations are ongoing, trading the stock is in a bit of...
2/13/2026, 11:22 AM
by MTES
9
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.